CytoMed Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
GDTC sits 19% above its 52-week low of $0.68.
Summary
CytoMed Therapeutics received a Nasdaq notice on October 6, 2026, that its shares have traded below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 5, 2027, to regain compliance and may pursue a reverse stock split.
Key Events · Legal and Risk Events · GDTC
-
Nasdaq Minimum Bid Price Deficiency
Nasdaq notified CytoMed on October 6, 2026, that its ordinary shares failed to maintain the $1.00 minimum bid price for 30 consecutive business days (August 24 – October 5, 2026).
-
180-Day Compliance Period
The company has until April 5, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days.
-
Potential Reverse Stock Split
If compliance is not regained by April 5, 2027, CytoMed may be eligible for a second 180-day period, which could require implementing a reverse stock split.
-
Listing Risk Amid Financial Distress
This notice follows the September 30, 2026, 6-K that disclosed going-concern language and a reduced H1 2026 net loss of S$1.79 million, compounding the company's survival challenges.
Analysis · GDTC · Life Sciences
A Nasdaq notification has put CytoMed Therapeutics on notice that its ordinary shares traded below the $1.00 minimum bid price for 30 consecutive business days. The company now has 180 calendar days, until April 5, 2027, to regain compliance. For a micro-cap biotech already carrying going-concern language and a reduced H1 2026 net loss, this is a critical listing risk. A delisting would severely impair liquidity and access to capital, potentially accelerating financial distress. The company is considering all options, including a reverse stock split, which would mechanically raise the share price but often signals weakness and can further erode shareholder value.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 44.1% of the 299 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDTC was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.